| Discuss | Index | Tracked By |
Traders Send Select Stem Cell Shares Soaring
OPXA JNJ ABT NBS GILD PSTI BCRX NVAX ATHX GERN OSIR CUR Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 08, 10:30AM from (www.tickerspy.com) The absence of notable news didn't stop speculators in the stem cell sector on Monday. Select stem cell more ...
The Unusual Suspects
AMAG AAPL MU GILD ARG APD BIDU XNPT DENN Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - February 06, 12:23PM from (247wallst.com) This past week was filled with many surprises and earnings are still coming on strong. We wanted to look at some companies more ...
Earnings Highlights: Aflac, Cisco, Exxon, MasterCard, Shell, Time Warner ...
UL AFL MA CME TWX RDS.A V NWS CSCO AVP ITG WU GSK XOM Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - February 06, 11:40AM from (www.bloggingstocks.com) Here are some highlights from this past week's earnings coverage on BloggingStocks: Aflac Inc. (AFL) posted more ...
Dividend Stock Leaders and Laggards from the Week of Feb.1-5
APD BDK CMI EMR GCI WAG HOT LTD PNC ARG AZN RL MA NEM Linked by The Dividend Daily ( track newsfeed | ignore newsfeed ) - February 06, 05:30AM from (www.dividend.com) Here are some of the biggest dividend stock winners and losers from the week that just ended. Company more ...
Media Digest 2/5/2010 Reuters, WSJ, NYTimes, FT, Bloomberg
JPM GE BAC AMZN TM KFT GSK DB CMCSA GOOG Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - February 05, 03:49AM from (247wallst.com) Reuters: The economy probably added 5,ooo jobs last month. Reuters: Kraft (KFT) gained control over 75% of Cadbury shares. more ...
Stocks That Institutional Investors Love
TGT CVS UNP WMT GILD BNI Linked by Investopedia Stock Analysis ( track newsfeed | ignore newsfeed ) - February 04, 11:53AM from (stocks.investopedia.com) Looking at the stocks that institutional investors own can provide a good starting point for the everyday investor. more ...
Analyst Upgrades, Downgrades and Initiations: AOL, DWA, EMS, MET, OCNW, SYNA, V, WU ...
BHP SYNA IEX RTP PKX RHHBY ITG MWW KBW MET OCNW CYCC DWA EMS WU SEP G V AOL Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - February 04, 11:40AM from (www.bloggingstocks.com) Analyst Upgrades Barclays upgraded Visa (V) to overweight from equal weight following the Q1 report and guidance. The firm raised its target to $97 from $91. more ...
Swine Flu Antiviral Helps BioCryst Crush Estimates in Q4
BCRX APT RHHBY NVAX INO GNBT SVA NVS SNY Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 04, 10:35AM from (www.tickerspy.com) While select swine flu players have seen their pops and drops, BioCryst Pharmaceuticals (BCRX) may have emerged as the small-cap champion of the 2009 pandemic. more ...
Pfizer Feeling Frisky
FRX LLY PFE GSK Linked by Investopedia Stock Analysis ( track newsfeed | ignore newsfeed ) - February 04, 10:34AM from (stocks.investopedia.com) Investors are worried about Lipitor's patent running out, but Pfizer has many other ways to give your portfolio a rise. more ...
GlaxoSmithKline Benefits from the Flu During the Fourth Quarter
GSK Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - February 04, 10:20AM from (www.bloggingstocks.com) GlaxoSmithKline (GSK) announced Thursday that fourth-quarter earnings rocketed 66% thanks to sales of its swine flu vaccine. more ...
GlaxoSmithKline Reports Q4 Adj-EPS of 34.4P, vs. Consensus of 33.5P
GSK Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 04, 07:41AM from (www.streetinsider.com) more ...
BioCryst Pharma Posts Q4 EPS of $0.35, Beats Views; Revs Heavy
BCRX Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 04, 06:51AM from (www.streetinsider.com) more ...
BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
BCRX Posted by PR Newswire ( track newsfeed | ignore newsfeed ) - February 04, 06:45AM BIRMINGHAM, Ala., Feb. 4 /PRNewswire-FirstCall/ -- BioCryst more ...
Ten Questions About High Cholesterol
ABT MRK PFE AZN GSK Linked by Forbes ( track newsfeed | ignore newsfeed ) - February 03, 08:14PM from (www.forbes.com) The biggest heart risk factor still mystifies top scientists. Here's what you need to know. more ...
Highlights From PFE's Q4 Conference Call: Wyeth Integration Going Well; Issues Guidance Through 2012
PFE GSK Linked by StreetInsider ( track newsfeed | ignore newsfeed ) - February 03, 01:11PM from (www.streetinsider.com) more ...
Home Diagnostics Buyout Powers Diabetes Segment
NVO AMLN HDIX MNKD GNBT ARRY Linked by tickerspy blog ( track newsfeed | ignore newsfeed ) - February 03, 12:03PM from (www.tickerspy.com) Home Diagnositics (HDIX) is soaring today after the company announced a definitive merger agreement with Nipro Corporation. more ...
Analyst Upgrades, Downgrades and Initiations: ARM, KFT, LOW, OXY, UBS, UPS, VRSN ...
LOW MYL BCS HD SIVB ABX OXY MTN MAN RHHBY CITP VRSN BXP CHRW UPS KFT ARM UBS KNXA CCH Linked by BloggingStocks ( track newsfeed | ignore newsfeed ) - February 03, 11:00AM from (www.bloggingstocks.com) Analyst Upgrades Deutsche Bank upgraded United Parcel Service (UPS) to buy from hold on expectations the more ...
Humana's Disheartening Outlook
BMY HUM UNH ESRX AZN WLP MJN Linked by Forbes ( track newsfeed | ignore newsfeed ) - February 01, 07:14PM from (www.forbes.com) Some analysts see upside to EPS growth, but insurer's forecast misses The Street's consensus call. more ...
Humana's Healthier Results
BMY HUM UNH ESRX AZN WLP MJN Linked by Forbes ( track newsfeed | ignore newsfeed ) - February 01, 05:14PM from (www.forbes.com) Insurer reports bump in Q4 profit despite negative impact of high unemployment rate. more ...
Gilead Sciences Announces Large Buyback
GILD Linked by The Razor's Edge ( track newsfeed | ignore newsfeed ) - January 29, 02:23PM from (blog.ockhamresearch.com) We have had an Undervalued rating on Gilead Sciences for quite some time because it has a unique combination of attractive more ...
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | About | Register | My tickerspy | Logout | Web site design by LightMix |
| © 2010 Indie Research, LLC. All rights reserved. | |
---
Institutional Holdings Disclaimer Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter. Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time. tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors. THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, INDIE RESEARCH, LLC AND IT LICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS AND NON-INFRINGEMENT. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER INDIE RESEARCH, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICNESORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGAES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.
|
|